Peppermint Homepage

CellAct Pharma GmbH


Peppermint contact: Sebastian Rausch

CellAct Pharma GmbH

CellAct Pharma GmbH develops innovative therapeutics for the treatment of diseases with high unmet need, especially of certain cancers and inflammatory diseases.

CellAct's first clinical drug candidate is a small molecule compound, named CAP7.1, a prodrug of Etoposide that has potential to treat multiple types of cancer, particularly lung and cancers with Multi Drug Resistance. CAP7.1 inhibits Topoisomerase II and has demonstrated a unique mechanism of action independent of Etoposide effects, which makes it an appealing product candidate to advance into human clinical trials.

CAP7.1 is currently in clinical Phase I study for the treatment of various cancer diseases.